2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia

References

• . Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–141
   PubMed Web of Science ®Google Scholar
• . Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44(8):1038–1042
   PubMed Web of Science ®Google Scholar
• . Sarawate CA, Brewer KK, Yang W, . Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–934
   PubMed Web of Science ®Google Scholar
• . Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822–829
   PubMed Web of Science ®Google Scholar
• . Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68(8):1265–1270
   PubMed Web of Science ®Google Scholar
• . Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49(1):105–111
   PubMedGoogle Scholar
• . Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol. 2006;33(3):562–566
   Google Scholar
• . Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33(1):104–109
   PubMed Web of Science ®Google Scholar
• . Harrold LR, Andrade SE, Briesacher BA, . Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46
   PubMed Web of Science ®Google Scholar
• . Singh JA, Sarkin A, Shieh M, . Health care utilization in patients with gout. Semin Arthritis Rheum. 2011;40(6):501–511
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Bardin T, Pascual E, ; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–1324
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Pascual E, ; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301–1311
   PubMed Web of Science ®Google Scholar
• . Guyatt GH, Oxman AD, Vist GE, ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926
   PubMed Web of Science ®Google Scholar
• . Guyatt GH, Oxman AD, Kunz R, . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400
   PubMed Web of Science ®Google Scholar
• . Hamburger M, Baraf HS, Adamson TC 3rd, . 2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia. Postgraduate Medicine. 2011;123(4 suppl 1):3–36
   Google Scholar
• . Guyatt G, Oxman AD, Akl EA, . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94
   PubMed Web of Science ®Google Scholar
• . Balshem H, Helfand M, Schünemann HJ, . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406
   PubMed Web of Science ®Google Scholar
• . Guyatt GH, Oxman AD, Kunz R, ; GRADE Working Group. Going from evidence to recommendations. BMJ. 2008;336(7652):1049–1051
   PubMed Web of Science ®Google Scholar
• . Schünemann HJ, Oxman AD, Brozek J, ; GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–1110
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120–1126
   PubMed Web of Science ®Google Scholar
• . Dirken-Heukensfeldt KJ, Teunissen TA, van de Lisdonk H, Lagro-Janssen AL. “Clinical features of women with gout arthritis.” A systematic review. Clin Rheumatol. 2010;29(6):575–582
   Google Scholar
• . Conway N, Schwartz S. Diagnosis and management of acute gout. Med Health R. I. 2009;92(11):356–358
   Google Scholar
• . Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75( suppl 5):S17–S21
   PubMedGoogle Scholar
• . Ayvazian JH, Ayvazian IF. Changes in serum and urinary uric acid with the development of symptomatic gout. J Clin Invest. 1963;42:1835–1839
   Google Scholar
• . Urano W, Yamanaka H, Tsutani H, . The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9):1950–1953
   PubMed Web of Science ®Google Scholar
• . Chong YY, Fong KY, Thumboo J. The value of joint aspirations in the diagnosis and management of arthritis in a hospital-based rheumatology service. Ann Acad Med Singapore. 2007;36(2):106–109
   PubMed Web of Science ®Google Scholar
• . Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056–1058
   PubMed Web of Science ®Google Scholar
• . Ostović KT, Kaić G, Ostović I, Skoro M, Novak NP, Morović-Vergles J. The importance of urgent cytological examination of synovial fluids in differentiation inflammatory and non-inflammatory joint diseases. Coll Antropol. 2010;34(1):145–152
   Google Scholar
• . McBride MB, Rigden S, Haycock GB, . Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. Pediatr Nephrol. 1998;12(5):357–364
   Google Scholar
• . Williams SE, Reed AA, Galvanovskis J, . Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum. Hum Mol Genet. 2009;18(16):2963–2974
   PubMed Web of Science ®Google Scholar
• . Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23(2):192–202
   PubMed Web of Science ®Google Scholar
• . Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225–232
   PubMed Web of Science ®Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–748
   PubMed Web of Science ®Google Scholar
• . Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973–981
   PubMed Web of Science ®Google Scholar
• . Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103–108
   PubMed Web of Science ®Google Scholar
• . Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38(8):1298–1315
   Google Scholar
• . Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, post-menopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305–1309
   PubMed Web of Science ®Google Scholar
• . Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010;62(4):1069–1076
   PubMed Web of Science ®Google Scholar
• . Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–443
   PubMed Web of Science ®Google Scholar
• . Day RO. Adherence to urate-lowering therapy. South Med J. 2009;102(1):114–115
   Google Scholar
• . Silva L, Miguel ED, Peiteado D, . Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–474
   PubMedGoogle Scholar
• . Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18(1):287–292
   PubMed Web of Science ®Google Scholar
• . Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298–303
   PubMed Web of Science ®Google Scholar
• . Mellen PB, Bleyer AJ, Erlinger TP, . Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48(6):1037–1042
   PubMed Web of Science ®Google Scholar
• . Perlstein TS, Gumieniak O, Williams GH, . Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–1036
   PubMed Web of Science ®Google Scholar
• . Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens. 2006;20(12):937–945
   PubMed Web of Science ®Google Scholar
• . Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007;58(4):450–457
   Google Scholar
• . Colvine K, Kerr AJ, McLachlan A, . Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. N Z Med J. 2008;121(1285):73–81
   PubMedGoogle Scholar
• . Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170–180
   PubMed Web of Science ®Google Scholar
• . Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2):118–124
   Google Scholar
• . Kim SY, De Vera MA, Choi HK. Gout and mortality. Clin Exp Rheumatol. 2008;26(5 suppl 51):S115–S119
   Google Scholar
• . Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–892
   PubMed Web of Science ®Google Scholar
• . Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58(2):623–630
   PubMedGoogle Scholar
• . Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–1110
   PubMed Web of Science ®Google Scholar
• . Kuo CF, See LC, Luo SF, . Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49(1):141–146
   Google Scholar
• . Strasak A, Ruttmann E, Brant L, ; VHM&PP Study Group. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54(2):273–284
   Web of Science ®Google Scholar
• . Strasak AM, Kelleher CC, Brant LJ, ; VHM&PP Study Group. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008;125(2):232–239
   PubMedGoogle Scholar
• . Chien KL, Chen MF, Hsu HC, . Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008;54(2):310–316
   Google Scholar
• . Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567–1570
   PubMed Web of Science ®Google Scholar
• . Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361–362
   PubMed Web of Science ®Google Scholar
• . Niskanen L, Laaksonen DE, Lindström J, . Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care. 2006;29(3):709–711
   Google Scholar
• . Hernández-Cuevas CB, Roque LH, Huerta-Sil G, . First acute gout attacks commonly precede features of the metabolic syndrome. J Clin Rheumatol. 2009;15(2):65–67
   Google Scholar
• . Nan H, Qiao Q, Söderberg S, . Serum uric acid and components of the metabolic syndrome in non-diabetic populations in Mauritian Indians and Creoles and in Chinese in Qingdao, China. Metab Syndr Relat Disord. 2008;6(1):47–57
   Google Scholar
• . Rho YH, Choi SJ, Lee YH, . The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20(6):1029–1033
   Google Scholar
• . Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413
   PubMed Web of Science ®Google Scholar
• . Obermayr RP, Temml C, Knechtelsdorfer M, . Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant. 2008;23(4):1265–1273
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database Syst Rev. 2006;(4):CD006190
   Google Scholar
• . Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008;(2):CD005521
   Google Scholar
• . Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068
   PubMed Web of Science ®Google Scholar
• . Finkelstein Y, Aks SE, Hutson JR, . Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407–414
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38(6):411–419
   PubMed Web of Science ®Google Scholar
• . Colcrys [package insert]. Philadelphia, PA: AR Scientific, Inc. A URL Pharma company; 2009
   Google Scholar
• . Montiel V, Huberlant V, Vincent MF, Bonbled F, Hantson P. Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management. Clin Toxicol (Phila). 2010;48(8):845–848
   PubMed Web of Science ®Google Scholar
• . Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7–8):1466–1469
   PubMed Web of Science ®Google Scholar
• . Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006;19(4):515–517
   Google Scholar
• . McKinnell J, Tayek JA. Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis. J Clin Rheumatol. 2009;15(6):303–305
   Google Scholar
• . Van der Velden W, Huussen J, Ter Laak H, de Sévaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med. 2008;66(5):204–206
   PubMed Web of Science ®Google Scholar
• . Chen SC, Huang MC, Fan CC. Potentially fatal interaction between colchicine and disulfiram. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1281
   PubMed Web of Science ®Google Scholar
• . Alayli G, Cengiz K, Cantürk F, Durmuç D, Akyol Y, Menekçe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7–8):1358–1361
   PubMed Web of Science ®Google Scholar
• . Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13(5):266–268
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Allopurinol. http://[email protected]. Accessed November 30, 2001
   Google Scholar
• . Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals North America, Inc; 2009
   Google Scholar
• . Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3–7
   PubMed Web of Science ®Google Scholar
• . Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585–591
   PubMedGoogle Scholar
• . Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2):61–65
   PubMed Web of Science ®Google Scholar
• . Wu EQ, Patel PA, Mody RR, . Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032–1040
   PubMed Web of Science ®Google Scholar
• . Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48( suppl 2):ii9–ii14
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30–38
   PubMed Web of Science ®Google Scholar
• . Gaffo AL, Saag KG. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evid. 2010;4:25–36
   Google Scholar
• . Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22–34
   PubMedGoogle Scholar
• . Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88–102
   PubMed Web of Science ®Google Scholar
• . Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J. 2008;49(5):384–387
   PubMed Web of Science ®Google Scholar
• . Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11(2):135–140
   PubMedGoogle Scholar
• . Reinders MK, Haagsma C, Jansen TL, . A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892–897
   PubMed Web of Science ®Google Scholar
• . Arroll B, Bennett M, Dalbeth N, Hettiarachchi D, Ben C, Shelling G. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. J Prim Health Care. 2009;1(4):315–318
   Google Scholar
• . Paisansinsup T, Schousboe JT. Adverse reactions to allopurinol are not increased in patients exposed to doses higher than recommended for creatinine clearance: a retrospective study of a large urban multi-specialty group. In: ACR/ARHP Scientific Meeting 2011; November 5–9, 2011; Chicago, IL
   Google Scholar
• . Becker MA, Schumacher HR, Espinoza LR, . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–1282
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188–194
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Becker MA, Wortmann RL, . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548
   PubMed Web of Science ®Google Scholar
• . Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009;11(4):236
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Probenecid. http://[email protected]. Accessed November 30, 2011
   Google Scholar
• . Wason S, Faulker RD, Brimhall DB, Davis MW. No dosing adjustments are required for colchicine in patients over age 60 years compared to younger adults on the basis of age and mild renal impairment. In: ACR/ARHP Scientific Meeting 2011; November 5–9, 2011; Chicago, IL. Abstract 1017
   Google Scholar
• . Wason S, Faulkner RD, Davis MW. Colchicine dosing guidelines for gout patients with varying degrees of renal impairment based on pharmacokinetic data. Data in: ACR/ARHP Scientific Meeting; Chicago, IL; 2011. Abstract 2581
   Google Scholar
• . Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol. 2006;33(7):1341–1345
   PubMed Web of Science ®Google Scholar
• . Jutabha P, Anzai N, Kitamura K, . Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010;285(45):35123–35132
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR, Benjamin KL, . Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041–1048
   PubMed Web of Science ®Google Scholar
• . Krystexxa [package insert]. East Brunswick, NJ: Savient Pharmaceuticals; 2010
   Google Scholar
• . Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287–1289
   PubMed Web of Science ®Google Scholar
• . Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol. 2007;62(3):437–443
   Google Scholar
• . Chen SY, Chen CL, Shen ML. Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol. 2007;26(9):1453–1457
   Google Scholar
• . Fraile JM, Torres RJ, de Miguel ME, . Metabolic syndrome characteristics in gout patients. Nucleosides Nucleotides Nucleic Acids. 2010;29(4–8):325–329
   Google Scholar
• . Anagnostopoulos I, Zinzaras E, Alexiou I, . The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98
   PubMedGoogle Scholar
• . Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22(2):165–172
   PubMed Web of Science ®Google Scholar
• . Rentzos M, Nikolaou C, Anagnostouli M, . Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006;108(6):527–531
   PubMed Web of Science ®Google Scholar
• . Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166(5):561–567
   PubMed Web of Science ®Google Scholar
• . Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15(1):22–24
   PubMed Web of Science ®Google Scholar
• . Annemans L, Spaepen E, Gaskin M, . Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–966
   PubMed Web of Science ®Google Scholar
• . Keenan RT, O'Brien WR, Lee KH, . Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155–163
   PubMed Web of Science ®Google Scholar
• . Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–59
   PubMed Web of Science ®Google Scholar
• . Kanbay M, Ozkara A, Selcoki Y, . Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–1233
   PubMedGoogle Scholar
• . Uetake D, Ohno I, Ichida K, . Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49(2):89–94
   PubMedGoogle Scholar
• . Hamada T, Ichida K, Hosoyamada M, . Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21(10):1157–1162
   PubMed Web of Science ®Google Scholar
• . Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–677
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854–1860
   PubMed Web of Science ®Google Scholar
• . Wollstein R, Chaimsky G, Carlson L, Watson HK, Wollstein G, Saleh J. Evaluating short-term pain after steroid injection. Am J Orthop (Belle Mead NJ). 2007;36(3):128–131
   Google Scholar
• . Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007;56(9):1179–1186
   Google Scholar
• . Goicoechea M, de Vinuesa SG, Verdalles U, . Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393
   PubMed Web of Science ®Google Scholar
• . Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26(9):1459–1465
   PubMed Web of Science ®Google Scholar
• . Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38(5):904–910
   PubMed Web of Science ®Google Scholar
• . Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet. 2008;47(2):111–118
   PubMed Web of Science ®Google Scholar
• . Sundy JS, Becker MA, Baraf HS, . Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882–2891
   PubMed Web of Science ®Google Scholar
• . Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–2432
   PubMed Web of Science ®Google Scholar
• . Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592–1601
   PubMed Web of Science ®Google Scholar
• . Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008;10(11):1102–1107
   Google Scholar
• . Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619–1632
   PubMed Web of Science ®Google Scholar